Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

BACKGROUND: Prognosis of metastatic non-small cell lung cancer significantly improved with the availability of checkpoint inhibitors (anti-PD-1/PD-L1). Unfortunately, reliable biomarkers to predict treatment benefit are lacking. PATIENTS AND METHODS: We prospectively collected clinical and laborator...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Manag Res
Asıl Yazarlar: Diem, Stefan, Fässler, Mirjam, Hasan Ali, Omar, Siano, Marco, Niederer, Rebekka, Berner, Fiamma, Roux, Guillaume-Alexandre, Ackermann, Christoph Jakob, Schmid, Sabine, Güsewell, Sabine, Früh, Martin, Flatz, Lukas
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234997/
https://ncbi.nlm.nih.gov/pubmed/30519101
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S179767
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller